TG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Beats Expectations By $2.19 EPS

TG Therapeutics (NASDAQ:TGTX) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19, Zacks reports. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.02 earnings per share. TG Therapeutics updated its FY 2025 guidance to EPS.

TG Therapeutics Trading Down 3.1%

NASDAQ:TGTX opened at $33.69 on Tuesday. The business’s 50-day moving average is $33.55 and its two-hundred day moving average is $34.78. The firm has a market capitalization of $5.35 billion, a PE ratio of 91.05 and a beta of 1.97. TG Therapeutics has a 12 month low of $22.92 and a 12 month high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.64% of the company’s stock.

Institutional Trading of TG Therapeutics

Large investors have recently bought and sold shares of the company. Corient Private Wealth LLC lifted its stake in shares of TG Therapeutics by 98.2% in the second quarter. Corient Private Wealth LLC now owns 80,704 shares of the biopharmaceutical company’s stock worth $2,905,000 after acquiring an additional 39,987 shares in the last quarter. E Fund Management Co. Ltd. raised its position in shares of TG Therapeutics by 23.6% in the 2nd quarter. E Fund Management Co. Ltd. now owns 21,009 shares of the biopharmaceutical company’s stock valued at $756,000 after purchasing an additional 4,013 shares in the last quarter. Engineers Gate Manager LP boosted its stake in shares of TG Therapeutics by 138.2% during the 2nd quarter. Engineers Gate Manager LP now owns 17,492 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 10,148 shares during the last quarter. Boothbay Fund Management LLC boosted its stake in shares of TG Therapeutics by 16.3% during the 2nd quarter. Boothbay Fund Management LLC now owns 71,051 shares of the biopharmaceutical company’s stock valued at $2,557,000 after buying an additional 9,963 shares during the last quarter. Finally, Brevan Howard Capital Management LP grew its position in shares of TG Therapeutics by 36.4% during the second quarter. Brevan Howard Capital Management LP now owns 60,120 shares of the biopharmaceutical company’s stock worth $2,164,000 after buying an additional 16,047 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

TGTX has been the subject of several recent analyst reports. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a research note on Thursday, July 10th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday. HC Wainwright started coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. B. Riley lifted their price target on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.